GOSS Share Price Performance
US$2.00
1.21 (153.07%)
75.1% undervalued intrinsic discount
US$8.03
Fair Value
Price US$2.00
AnalystConsensusTarget US$8.03
Fair ValueUS$8.03
Share PriceUS$2.00
75.1% undervalued intrinsic discount
GOSS Community Narratives
AN
Fair Value US$8.03 75.1% undervalued intrinsic discount
Phase III Trials And Global Collaborations Will Expand Treatment Horizons
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
GOSS Community Fair Values
- US$8.03FV75.1% undervalued intrinsic discount7.49%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative12users have followed this narrative11 days ago author updated this narrative
Recent GOSS News & Updates
No updates
Gossamer Bio, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.23
- Gross Margin
- 100.00%
- Net Profit Margin
- -41.13%
- Debt/Equity Ratio
- -3,164.2%
Gossamer Bio, Inc. Competitors
About GOSS
- Founded
- 2015
- Employees
- 145
- CEO
- WebsiteView website
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.7%
- 1 Year: 17.5%
- Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading